India Positioned to Ride a $300 Billion Biopharma Patent Cliff, Vallum Capital Report Says

A generational opening for Indian biotech

India is uniquely placed to capitalise on a global genomics revolution and a looming wave of drug-patent expiries worth some $300 billion, according to a report from Vallum Capital released on 29 July 2026. The report frames the coming patent cliff — and the aggressive biopharma dealmaking it is driving — as one of the largest growth windows Indian drugmakers have ever faced.

The argument rests on a shift in what is expiring. For decades, India's pharmaceutical industry built its global reputation on making low-cost generic versions of small-molecule drugs once their patents lapsed. The medicines now approaching the edge of the cliff are different: biologics, gene therapies and precision-oncology drugs — complex, high-value products that are far harder to copy, but also far more valuable to whoever can.

Why India, and why now

India's structural advantage, the report notes, is manufacturing. The country hosts more WHO-certified pharmaceutical plants than any other nation on earth, the backbone of a decades-old model in which science invented in the West is scaled and delivered by India. As biologics and advanced therapies come off patent, that manufacturing depth could translate into a commanding position in biosimilars and complex generics — provided Indian firms can master the more demanding science and regulatory pathways these products require.

The report situates the opportunity against a frothy global backdrop. Biopharma mergers and acquisitions reached about $106 billion across 201 deals in the first half of 2026 alone, it says, while biotech IPOs raised more capital in that half-year than the entire sector managed across all of 2025 — a signal of how much money is chasing the next wave of therapies.

Building the capabilities

Crucially, India is no longer content to be only the world's factory. The report points to initiatives designed to move the country up the value chain into discovery and advanced biology. The Genome India Project has been mapping 10,000 genomes across 99 ethnic groups, building a genetic reference base tailored to Indian populations — essential raw material for precision medicine. The Biopharma Shakti scheme, meanwhile, is aimed at strengthening domestic capabilities in biologics, gene therapies and other frontier areas.

Those efforts dovetail with tangible recent milestones in Indian biotech, from indigenously developed CAR-T cell therapies to a growing pipeline of gene-therapy and precision-oncology work at domestic firms and institutes. The through-line is a country trying to graduate from copying molecules to engineering biology.

The gap between promise and delivery

The report is an outlook, not a guarantee, and the caveats are real. Biologics and gene therapies demand sophisticated process science, cold chains, and clinical and regulatory expertise that go well beyond the generics playbook. Building genuinely novel therapeutics — rather than biosimilars — requires sustained R&D spending, a deeper venture ecosystem, and a tolerance for long, expensive failure that Indian pharma has historically been cautious about.

There is also competition. China, in particular, has poured resources into biologics and cell-and-gene therapy manufacturing, and the same patent cliff is visible to every major generics and biosimilars player worldwide. India's manufacturing base is a strong starting hand, but it is not, by itself, a winning one.

The bottom line

What the Vallum Capital report captures is a moment of alignment: a historic volume of high-value drugs losing protection, a global rush of capital into biopharma, and an Indian sector that has both the manufacturing scale and, increasingly, the policy scaffolding to reach for more of the value. Whether India converts that alignment into leadership in biologics and precision medicine — or simply supplies the world's biosimilars at scale — will be one of the defining questions for its deep-tech economy over the next decade.

Sources

• IANS (ianslive): https://ianslive.in/india-set-to-lead-genomics-revolution-amid-global-patents-expiry-wave--20260729114256
• Prokerala: https://www.prokerala.com/news/articles/a1793790.html
• THIP Media: https://www.thip.media/news/india-set-to-lead-genomics-revolution-amid-global-patents-expiry-wave-report/150206/
• New Kerala: https://www.newkerala.com/news/a/india-set-lead-genomics-revolution-amid-global-patents-420.htm